Urate transporter inhibitor lesinurad is a selective peroxisome proliferator-activated receptor gamma modulator (sPPARγM) in vitro
Abstract Gout is the most common arthritic disease in human but was long neglected and therapeutic options are not satisfying. However, with the recent approval of the urate transporter inhibitor lesinurad, gout treatment has experienced a major innovation. Here we show that lesinurad possesses cons...
Guardado en:
Autores principales: | Pascal Heitel, Leonie Gellrich, Jan Heering, Tamara Goebel, Astrid Kahnt, Ewgenij Proschak, Manfred Schubert-Zsilavecz, Daniel Merk |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/99894e9ac49c488b912c6cbbe9902276 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Oxaliplatin neurotoxicity involves peroxisome alterations. PPARγ agonism as preventive pharmacological approach.
por: Matteo Zanardelli, et al.
Publicado: (2014) -
Alteration of PPAR‐GAMMA (PPARG; PPARγ) and PTEN gene expression in acute myeloid leukemia patients and the promising anticancer effects of PPARγ stimulation using pioglitazone on AML cells
por: Shadi Esmaeili, et al.
Publicado: (2021) -
Allosteric modulation of the farnesoid X receptor by a small molecule
por: Matthias Gabler, et al.
Publicado: (2018) -
Prenatal polycyclic aromatic hydrocarbon, adiposity, peroxisome proliferator-activated receptor (PPAR) γ methylation in offspring, grand-offspring mice.
por: Zhonghai Yan, et al.
Publicado: (2014) -
Peroxisome proliferator-activated receptor (PPAR) γ and PPARα agonists modulate mitochondrial fusion-fission dynamics: relevance to reactive oxygen species (ROS)-related neurodegenerative disorders?
por: Juan M Zolezzi, et al.
Publicado: (2013)